Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Syrian rue seeds contain beta-carboline alkaloids including harmine and harmaline that strongly inhibit monoamine oxidase enzymes, reducing breakdown of serotonin and norepinephrine. These compounds also inhibit DNA topoisomerase I and demonstrate antimicrobial activity through respiratory chain disruption.
Reported Benefits (Provisional)
Origin & History
Syrian Rue (Peganum harmala) is a perennial herbaceous plant native to the arid and semi-arid regions of the Mediterranean, Central Asia, and the Middle East. Its seeds are notable for containing harmala alkaloids, which are potent monoamine oxidase inhibitors (MAOIs). This unique phytochemical profile underpins its traditional uses and emerging interest in neurological and mood support.
Research Narrative (Provisional)
Research on Syrian Rue primarily focuses on its harmala alkaloids, with in vitro and animal studies demonstrating MAOI activity, neuroprotective effects, and antimicrobial properties. While promising for neurological and mood support, human clinical trials are limited, and its psychoactive potential necessitates careful study and controlled application.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Alkaloids: Harmine, Harmaline, Tetrahydroharmine (potent MAOIs) - Essential Fatty Acids - Flavonoids and Phenolic Compounds - Minerals: Iron, Magnesium, Potassium, Zinc
Reported Mechanism (Provisional)
The primary beta-carboline alkaloids harmine, harmaline, and harmol inhibit monoamine oxidase (MAO) enzymes, preventing degradation of serotonin and norepinephrine neurotransmitters. These compounds also inhibit human DNA topoisomerase I, affecting cellular DNA synthesis and repair processes. Additionally, harmaline and related alkaloids demonstrate dopamine receptor (DRD2) antagonism and disrupt parasitic respiratory chains.
Clinical Narrative (Provisional)
Current research consists primarily of in vitro and animal studies, with limited human clinical trial data available in published literature. Laboratory studies demonstrate MAO inhibition, DNA topoisomerase I inhibition, and antimicrobial activity at concentrations of 12.5-25 μg/mL. In vitro studies show trypanosomicidal activity against drug-resistant Trypanosoma cruzi strains and antibacterial effects against both gram-positive and gram-negative bacteria. Human clinical evidence remains insufficient to establish therapeutic efficacy or optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.